QuidelOrtho Corp (QDEL) — SEC Financial Statements & Analysis

QuidelOrtho Corp (QDEL) is a in vitro & in vivo diagnostic substances company. QuidelOrtho Corp trades on Nasdaq as: QDEL. QuidelOrtho Corp (QDEL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, QuidelOrtho Corp carries a market cap of $1.20B, a P/E ratio of -1.14x, a P/B ratio of 0.67x, a P/S ratio of 0.45x, an enterprise value of $3.96B, and an EV/EBITDA multiple of -10.70x. On profitability, it posts a gross margin of 44.60%, an operating margin of -30.84%, a net margin of -39.20%, a Return on Equity (ROE) of -45.91%, a Return on Assets (ROA) of -17.34%, and a Return on Invested Capital (ROIC) of -16.66%. Per share, it reports EPS of $-15.35, diluted EPS of $-15.35, free cash flow per share of $-3.09, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -2.46% year-over-year, net income growth of 124.79% year-over-year, and EPS growth of 122.81% year-over-year. On the balance sheet, it maintains a current ratio of 1.39x, a quick ratio of 0.51x, working capital of $383.20M, a debt-to-equity ratio of 2.22x, a debt ratio of 0.69, an interest coverage ratio of -4.06x, free cash flow of $-211.20M (TTM), and net debt of $2.77B. Figures sourced from SEC EDGAR.

Market Cap

$1.20B

P/E TTM

-1.14x

EPS TTM

$-15.35

P/B TTM

0.67x

ROE TTM

-45.91%

ROA TTM

-17.34%

Debt To Equity

2.22x

Free Cash Flow TTM

$-211.20M

Net Revenue TTM Growth 1Y

-2.46%

Data as of 2026-06-30 · Source: SEC EDGAR